Canada Markets closed

KetamineOne Capital Limited (MEDI.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
0.4650-0.0550 (-10.58%)
At close: 1:50PM EDT
Full screen
Previous Close0.5200
Open0.5000
Bid0.4600 x N/A
Ask0.4800 x N/A
Day's Range0.4650 - 0.5000
52 Week Range0.1300 - 1.9000
Volume7,013
Avg. Volume0
Market Cap48.058M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0530
Earnings DateJun. 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ketamine One Features Biostrap as Part of Inaugural Research Studies

    The Observational Studies Will Collect Advanced Biometric Data in Upcoming Depression and PTSD StudiesVANCOUVER, British Columbia, Oct. 20, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it will be conducting its previously announced single arm, observational, biometric r

  • GlobeNewswire

    Ketamine One Launching Two Inaugural Research Studies

    The Single-Arm Studies Will Be Focused on Treatment-Resistant Depression and Post-Traumatic Stress DisorderVANCOUVER, British Columbia, Oct. 14, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it will be launching a single arm, open label study of patients with post-trauma

  • GlobeNewswire

    Ehave Hires Contract Research Organization To Conduct Ketamine Clinical Trial In Miami, Florida

    Ehave one of the first companies to pioneer the collection of certain data points, as well as to seek to understand how ketamine can potentially resolve issues in the brain through a process called neuroplasticityMIAMI, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has hired KGK Science Inc., a contract research organization (CRO) that is wholly-owned by Ketamin